嘉必優(688089.SH):擬購買歐易生物65.00%的股權 11月12日起復牌
格隆匯11月11日丨嘉必優(688089.SH)公佈,公司擬以發行股份及支付現金的方式向王樹偉、董棟、肖雲平、王修評、靳超、史賢俊、上海帆易、寧波睿歐、寧波歐潤、國藥二期、南通東證、蘇州鼎石、上海生物、上海聖祁共14名交易對方購買歐易生物65.00%的股權,並募集配套資金。標的資產的最終交易價格將以符合《證券法》規定的資產評估機構出具的評估報吿的評估結果為基礎,經交易雙方充分協商確定。
標的公司以多組學技術與大數據分析技術為基礎,為生命科學、醫學、食品、化粧品等領域應用研究提供多層次的多組學分析技術服務,同時自主開發了遺傳病診斷試劑盒產品系列。標的公司依靠創新驅動的研發戰略導向,圍繞中心法則實現了多組學的貫通,在行業內成功打造出“創新多組學”的優質品牌,報吿期內已累計與超過2,000家高等院校、科研院所、醫院與企業建立了深厚合作關係。
通過本次交易,上市公司與標的公司憑藉自身的業務與技術優勢,能夠為彼此賦能和引流,形成生物技術、數據信息、客户資源、市場渠道等多方面的協同效應。同時,上市公司主營業務將進一步向科研技術服務領域延伸,打造“技術服務+創新功能性高分子挖掘+產品輸出”一體化的產業服務平台,實現產品和服務的協同互補,為客户提供完整解決方案。上市公司與標的公司藉助彼此積累的核心技術能力和特定優勢資源稟賦,實現雙方在技術、信息、市場、產品等資源的有效整合,強化公司技術研發實力和服務客户能力,提升生產效率,補鏈強鏈,有效擴大公司整體規模,增強市場競爭力。
根據相關規定,經向上海證券交易所申請,公司股票將於2024年11月12日開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.